SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome The treatment combines SciSparc's Palmitoylethanolamide (PEA), the active pharmaceutical ingredient of its proprietary CannAmide™, and Clearmind’s MEAI, a novel proprietary psychedelic treatment for...

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary...